Veronica Hackethal, MD
A new optical technology called multiphoton microscopy (MPM) could allow for noninvasive, painless, and rapid diagnosis of basal cell carcinomas (BCCs) in the clinic, according to a small pilot study published online April 24 in JAMA Dermatology.
Alexander M. Castellino, PhD
Two studies published online May 13 in the Lancet Oncology provide data that impacts the clinical management of patients with advanced basal cell carcinoma (BCC).
One study, known as BOLT, profiles a new drug that is awaiting approval: sonidegib (Odomzo, Novartis). The manufacturer has filed for approval in Australia, the European Union, Switzerland, and the United States.
The other study, known as STEVIE, provides long-term safety data for vismodegib (Erivedge, Genentech), which was launched in 2012, from a setting representative of routine clinical practice.
Both drugs act as inhibitors of the Hedgehog signaling pathway.
Roxanne Nelson
June 15, 2012 — Vismodegib (Erivedge) "is the greatest advance in therapy yet" for the treatment of basal cell carcinoma (BCC), according to an editorial published in the June 7 issue of the New England Journal of Medicine.
COMMENTARY
Graeme M. Lipper, MD
Increased Risk of Migraine in Patients With Psoriasis: A Danish Nationwide Cohort Study.
Egeberg A, Mallbris L, Hilmar Gislason G, Skov L, Riis Hansen P
J Am Acad Dermatol. 2015;73:829-835